Efficacy and safety of abacavir-containing combination antiretroviral therapy as first-line treatment of HIV infected children and adolescents: a systematic review and meta-analysis

BMC Infectious Diseases

Charles S. Wiysonge²  Tolulope A. Balogun²  Anel Schoonees¹  Olatunji O. Adetokunboh² 

[1] Centre for Evidence-based Health Care, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town 7505, South Africa;Division of Community Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town 7505, South Africa

关键词: Safety;    Efficacy;    HIV;    Antiretroviral therapy;    Adolescents;    Children;    Abacavir;   

Others  :  1232805
DOI  :  10.1186/s12879-015-1183-6

 received in 2015-04-02, accepted in 2015-10-06,  发布年份 2015

【 摘 要 】

Background

Abacavir is one of the recommended nucleoside reverse transcriptase inhibitors (NRTIs) for the treatment of HIV infections among children and adolescents. However, there are concerns that the antiviral efficacy of abacavir might be low when compared to other NRTIs especially among children. There are also concerns that abacavir use may lead to serious adverse events such as hypersensitivity reactions and has potential predisposition to developing cardiovascular diseases

Methods

We searched four electronic databases, four conference proceedings and two clinical trial registries in August 2014, without language restrictions. Experimental and observational studies with control groups that examined the efficacy and safety of abacavir-containing regimens in comparison with other NRTIs as first-line treatment for HIV-infected children and adolescents aged between one month and eighteen years were eligible. Two authors independently screened search results, extracted data and assessed the risk of bias of included studies using a pre-specified, standardised data extraction form and validated risk of bias tools. We also assessed the quality of evidence per outcome with the GRADE tool.

Results

We included two randomised controlled trials (RCTs) and two analytical cohort studies with a total of 10,595 participants. Among the RCTs we detected no difference in virologic suppression after a mean duration of 48 weeks between abacavir- and stavudine-containing regimens (2 trials; n = 326: RR 1.28; 95 % CI 0.67–2.42) with significant heterogeneity (P = 0.02; I ²  = 81 %). We also found no significant differences between the two groups for adverse events and death. After five years of follow-up, virologic suppression improved with abacavir (1 trial; n = 69: RR 1.96; 95 % CI 1.11–3.44). For cohort studies, we detected that the virologic suppression activity of abacavir was less effective than stavudine in both the lopinavir/ritonavir (1 study, n = 2165: RR 0.79, 95 % CI 0.67–0.92) and efavirenz sub-groups (1 study, n = 3204: RR 0.79, 95 % CI 0.67–0.92) respectively. The quality of evidence from RCTs was moderate for virologic suppression but low for death and adverse events, while that of cohort studies was low for all three these outcomes.

Conclusions

Available evidence showed little or no difference between abacavir-containing regimen and other NRTIs regarding efficacy and safety when given to children and adolescents as a first-line antiretroviral therapy.

【 授权许可】

   
2015 Adetokunboh et al.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

【 参考文献 】

• [1]UNAIDS. The gap report. 2014. http://www. unaids.org/sites/default/files/media_asset/UNAIDS_Gap_report_en.pdf webcite
• [2]UNICEF. Towards an AIDS-free generation – children and AIDS: sixth stocktaking report, 2013. 2013. http://www. unicef.org/gambia/Towards_an_AIDS-free_generation_-_Children_and_AIDSSixth_Stocktaking_Report_2013.pdf webcite
• [3]WHO. Global update on the health sector response to HIV, 2014. 2014. http://apps. who.int/iris/bitstream/10665/128494/1/9789241507585_eng.pdf?ua=1 webcite
• [4]WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. 2013. http://apps. who.int/iris/bitstream/10665/85321/1/9789241505727_eng.pdf?ua=1 webcite
• [5]Daluge SM, Good SS, Faletto MB, Miller WH, St Clair MH, Boone LR et al.. 1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity. Antimicrob Agents Chemother. 1997; 41:1082-93.
• [6]WHO. Antiretroviral therapy for HIV infection in infants and children: towards universal access. Recommendations for a public health approach. 2006. http://www. who.int/hiv/pub/guidelines/art/en/ webcite
• [7]WHO. Rapid advice: antiretroviral therapy for HIV infection in adults and adolescents. 2009. http://www. who.int/hiv/pub/arv/rapid_advice_art.pdf webcite
• [8]Saag MS, Sonnerborg A, Torres RA, Lancaster D, Gazzard BG, Schooley RT et al.. Antiretroviral effect and safety of abacavir alone and in combination with zidovudine in HIV‐infected adults. AIDS. 1998; 12:F203-9.
• [9]Hewitt RG. Abacavir hypersensitivity reaction. Clin Infect Dis. 2002; 34:1137-42.
• [10]Hughes CA, Foisy MM, Dewhurst N, Higgins N, Robinson L, Kelly DV et al.. Abacavir hypersensitivity reaction: an update. Ann Pharmacother. 2008; 42:387-96.
• [11]Clay PG. The abacavir hypersensitivity reaction: a review. Clin Ther. 2002; 24:1502-14.
• [12]Nahirya-Ntege P, Musiime V, Naidoo B, Bakeera-Kitaka S, Nathoo K, Munderi P et al.. Low incidence of abacavir hypersensitivity reaction among African children initiating antiretroviral therapy. Pediatr Infect Dis J. 2011; 30:535-7.
• [13]Munderi P, Snowden WB, Walker AS, Kityo C, Mosteller M, Kabuye G et al.. Distribution of HLA-B alleles in a Ugandan HIV-infected adult population: NORA pharmacogenetic substudy of DART. Trop Med Int Health. 2011; 16:200-4.
• [14]Technau KG, Lazarus E, Kuhn L, Abrams EJ, Sorour G, Strehlau R et al.. Poor early virologic performance and durability of abacavir-based first-line regimens for HIV-infected children. Pediatr Infect Dis J. 2013; 32:851-5.
• [15]Technau KG, Schomaker M, Kuhn L, Moultrie H, Coovadia A, Eley B et al.. Virologic response in children treated with abacavir compared with stavudine-based antiretroviral treatment – a South African multi-cohort analysis. Pediatr Infect Dis J. 2014; 33:617-22.
• [16]Choi AI, Vittinghoff E, Deeks SG, Weekley CC, Li Y, Shlipak MG. Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons. AIDS. 2011; 25:1289-98.
• [17]Sabin CA, Worm SW, Weber R, Reiss P, El-Sadr W et al.. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet. 2008; 371:1417-26.
• [18]Cruciani M, Zanichelli V, Serpelloni G, Bosco O, Malena M, Mazzi R et al.. Abacavir use and cardiovascular disease events: a meta-analysis of published and unpublished data. AIDS. 2011; 25:1993-2004.
• [19]Ding X, Andraca-Carrera E, Cooper C, Miele P, Kornegay C, Soukup M et al.. No association of abacavir use with myocardial infarction: findings of an FDA meta-analysis. J Acquir Immune Defic Syndr. 2012; 61:441-7.
• [20]Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS. 2008; 22:F17-24.
• [21]Martin A, Amin J, Cooper DA, Carr A, Kelleher AD, Bloch M et al.. Abacavir does not affect circulating levels of inflammatory or coagulopathic biomarkers in suppressed HIV: a randomised clinical trial. AIDS. 2010; 24:2657.
• [22]Cruciani M, Mengoli C, Serpelloni G, Parisi SG, Malena M, Bosco O. Abacavir based triple nucleoside regimens for maintenance therapy in patients with HIV. Cochrane Database Syst Rev. 2013; 6:CD008270.
• [23]Adetokunboh O, Schoonees A, Wiysonge CS. Antiviral efficacy and safety of abacavir-containing combination antiretroviral therapy as first-line treatment of HIV infected children and adolescents: a systematic review protocol. Syst Rev. 2014; 3:87. BioMed Central Full Text
• [24]Shey MS, Kongnyuy EJ, Alobwede SM, Wiysonge CS. Co-formulated abacavir-lamivudine-zidovudine for initial treatment of HIV infection and AIDS. Cochrane Database Syst Rev. 2013; 3:CD005481.
• [25]Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. 2011. www. cochrane-handbook.org webcite
• [26]Wells, GA, Shea, B, O’Connell, D, Peterson, JE, Welch, V, Losos, M. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2000. http://www. ohri.ca/programs/clinical_epidemiology/oxford.asp webcite
• [27]Review Manager (RevMan) [Computer program]: The Nordic Cochrane Centre. Copenhagen: The Cochrane Collaboration; 2014 [Version 5.3].
• [28]Musiime V, Mulenga V, Kekitiinwa A, Cook A, Abongomera G, Thomason MJ et al.. CHAPAS 3: A randomised trial comparing stavudine vs zidovudine vs abacavir as NRTI backbone in NNRTI-based first-line ART in 478 HIV-infected children in Uganda and Zambia. Rev Antiviral Ther Infect Dis. 2014; 6:22.
• [29]Brennan AT, Maskew M, Long L, Sanne I, Fox MP, Conradie F. 24-month treatment outcomes amongst HIV-positive children and adolescent patients prescribed stavudine vs. abacavir. 20th International AIDS Conference, Melbourne, Australia 20 – 25 July 2014. http://pag.aids2014.org/EPosterHandler.axd?aid=2246. Accessed 15 Aug 2014.
• [30]Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009; 339:2535.
• [31]Comparison of dual nucleoside-analogue reverse-transcriptase inhibitor regimens with and without nelfinavir in children with HIV-1 who have not previously been treated: the PENTA 5 randomised trial. Lancet. 2002; 359:733.
• [32]Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children. AIDS. 2007; 21:947-55.
• [33]Flynn P, Komar S, Blanche S, Giaquinto C, Noguera-Julian A, Welch S et al.. Efficacy and Safety of Darunavir/Ritonavir at 48 Weeks in Treatment-Naive, HIV-1-infected Adolescents: Results from a Phase 2 Open-label Trial (DIONE). Pediatr Infect Dis J. 2014; 33:940-5.
• [34]Kline MW, Blanchard S, Fletcher CV, Shenep JL, McKinney RE, Brundage RC et al.. A phase I study of abacavir (1592U89) alone and in combination with other antiretroviral agents in infants and children with human immunodeficiency virus infection. AIDS Clinical Trials Group 330 Team. Pediatrics. 1999; 103:e47.
• [35]Musiime V, Cook A, Kayiwa J, Zangata D, Nansubuga C, Arach B et al.. Anthropometric measurements and lipid profiles to detect early lipodystrophy in antiretroviral therapy experienced HIV-infected children in the CHAPAS-3 trial. Antivir Ther. 2014; 19:269-76.
• [36]Neely M, Rutstein R, Del Bianco G, Heresi G, Barton T, Wiznia A et al.. Use of nucleoside reverse transcriptase inhibitor-only regimens in HIV-infected children and adolescents. Pediatr Infect Dis J. 2013; 32:e370-6.
• [37]First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial. Lancet Infect Dis. 2011; 11:273.
• [38]Sáez-Llorens X, Nelson RP, Emmanuel P, Wiznia A, Mitchell C, Church JA et al.. A randomized, double-blind study of triple nucleoside therapy of abacavir, lamivudine, and zidovudine versus lamivudine and zidovudine in previously treated human immunodeficiency virus type 1-infected children. The CNAA3006 Study Team. Pediatrics. 2001; 107:E4.
• [39]Moore DM, Hogg RS, Yip B, Wood E, Harris M, Montaner JSG. Regimen‐dependent variations in adherence to therapy and virological suppression in patients initiating protease inhibitor‐based highly active antiretroviral therapy. HIV Med. 2006; 7:311-6.
• [40]Hill A, Sawyer W. Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first‐line boosted highly active antiretroviral therapy based on protease inhibitors: meta‐regression analysis of 12 clinical trials in 5168 patients. HIV Med. 2009; 10:527-35.
• [41]Cruciani M, Mengoli C, Malena M, Serpelloni G, Parisi SG, Moyle G et al.. Virological efficacy of abacavir: systematic review and meta-analysis. J Antimicrob Chemother. 2014; 69:3169-80.
• [42]McPheeters ML, Kripalani S, Peterson NB, Idowu RT, Jerome RN, Potter SA et al.. Closing the quality gap: revisiting the state of the science (vol 3: quality improvement interventions to address health disparities). Agency for Healthcare Research and Quality, Rockville, MD; 2012. Evidence reports/technology assessments, no. 208.3. AHRQ Publication No. 12-E009-EF
• [43]Rennie D. CONSORT revised—improving the reporting of randomized trials. JAMA. 2001; 285:2006-7.